头颈癌放疗后原发性甲状腺功能减退的剂量-体积预测因素:一项系统综述
该系统综述检索截至2021年7月1日的文献,纳入29项观察性研究共4530例头颈癌患者,放疗后原发性甲状腺功能减退的平均粗发生率为41.4%(范围10%-57%)。甲状腺平均剂量和V50是最常提出的剂量学预测因素,甲状腺体积每增加1 cc,校正后发生风险的汇总OR为0.89(95%CI 0.85-0.93;p<0.001)。作者认为应个体化考虑甲状腺剂量-体积约束。
要点
- 放疗后原发性甲状腺功能减退平均粗发生率为41.4%(范围10%-57%)。
- 甲状腺平均剂量和V50是最常提出的剂量学预测因素。
- 甲状腺体积每增加1 cc,校正后OR为0.89(95%CI 0.85-0.93;p<0.001)。
核心结论
- 放疗后原发性甲状腺功能减退是头颈癌放疗后常见的晚期并发症。
- 尽量减少甲状腺的非预期照射对预防该晚期并发症至关重要。
- 作者认为头颈癌放疗计划中应考虑按甲状腺体积个体化的剂量-体积约束。
研究设计与样本
- 系统综述,检索Medline、EMBASE和Web of Science从建库至2021年7月1日的文献。
- 纳入29项观察性研究,共4530例头颈癌患者。
- 采用随机效应模型进行Meta分析,估计甲状腺体积作为放疗后甲状腺功能减退风险预测因素的汇总校正OR。
主要发现
- 中位随访时间范围为1.0至5.3年,放疗后原发性甲状腺功能减退的平均粗发生率为41.4%(范围10%-57%)。
- 多种放疗剂量-体积参数与放疗后原发性甲状腺功能减退相关,包括甲状腺平均剂量(Dmean)、最小剂量、V25、V30、V35、V45、V50、V30-60、VS45和VS60。
- 甲状腺Dmean和V50是最常提出的剂量学预测因素。
- 甲状腺体积每增加1 cc,放疗后原发性甲状腺功能减退风险的汇总校正OR为0.89(95%CI 0.85-0.93;p<0.001)。
关键数值与推荐
- 甲状腺体积每增加1 cc,校正后OR为0.89(95%CI 0.85-0.93;p<0.001)。
- 放疗后原发性甲状腺功能减退的平均粗发生率为41.4%(范围10%-57%)。
- 与放疗后原发性甲状腺功能减退相关的剂量-体积参数包括甲状腺Dmean、最小剂量、V25、V30、V35、V45、V50、V30-60、VS45和VS60。
临床怎么用
- 作者认为头颈癌放疗计划中应考虑按甲状腺体积个体化的剂量-体积约束。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This systematic review aims to identify radiation dose-volume predictors of primary hypothyroidism after radiotherapy in patients with head and neck cancer (HNC). MATERIALS AND METHODS: We performed a systematic literature search of Medline, EMBASE and Web of Science from database inception to July 1, 2021 for articles that discuss radiation dose-volume predictors of post-radiation primary hypothyroidism in patients with HNC. Data on the incidence, clinical risk factors and radiation dose-volume parameters were extracted. A meta-analysis was performed using the random-effects model to estimate the pooled odds ratio (OR) of thyroid volume as a predictor of the risk of post-radiation hypothyroidism, adjusted for thyroid radiation dosimetry. RESULTS: Our search identified 29 observational studies involving 4,530 patients. With median follow-up durations ranging from 1.0 to 5.3 years, the average crude incidence of post-radiation primary hypothyroidism was 41.4 % (range, 10 %-57 %). Multiple radiation dose-volume parameters were associated with post-radiation primary hypothyroidism, including the thyroid mean dose (Dmean), minimum dose, V25, V30, V35, V45, V50, V30-60, VS45 and VS60. Thyroid Dmean and V50 were the most frequently proposed dosimetric predictors. The pooled adjusted OR of thyroid volume on the risk of post-radiation primary hypothyroidism was 0.89 (95 % confidence interval, 0.85-0.93; p < 0.001) per 1 cc increment. CONCLUSION: Post-radiation primary hypothyroidism is a common late complication after radiotherapy for HNC. Minimizing inadvertent exposure of the thyroid gland to radiation is crucial to prevent this late complication. Radiation dose-volume constraints individualized for thyroid volume should be considered in HNC radiotherapy planning.
引用
- Chow JCH, Cheung KM, Cheung GTC, et al. Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. Clin Transl Radiat Oncol. 2022. PMID: 35128087. doi:10.1016/j.ctro.2022.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。